环丙沙星与帕珠沙星治疗脑卒中患者医院获得性肺炎的疗效评估

Prospective randomized controlled clinical trial of the efficacy and safety of pazufloxacin and ciprofloxacin in the treatment of hospital-acquired pneumonia

目的：评价帕珠沙星与环丙沙星对医院获得性肺炎（HAP）的临床价值。方法：采用前瞻性、临床随机对照的方法,试验组用帕珠沙星注射液300mg,iv gtt,bid;对照组用环丙沙星200mg,iv gtt,bid,疗程7~10d,评价其临床疗效及安全性。结果：帕珠沙星组痊愈率（77.59%vs 53.45%）,总有效率（89.66%vs 74.14%）,细菌学总清除率（93.02%vs 80.1%）,铜绿假单胞菌清除率（98.15%vs 75.0%）以及肺炎克雷伯菌清除率（97.78%vs 85.7%）均优于环丙沙星组,并具有统计学意义（P〈0.05或P〈0.01）,另外帕珠沙星组不良事件发生率要小于环丙沙星组（15.52%vs 27.59%）,具有统计学意义（P〈0.05）。其他症状大多轻微,可自行缓解,不影响临床研究。结论：帕珠沙星治疗医院获得性肺炎疗效确切并优于环丙沙星,尤其对铜绿假单胞杆菌、肺炎克雷伯菌引起的感染疗效更优,且不良反应较少,即帕珠沙星是较环丙沙星与HAP流行病原菌吻合度更高的氟喹诺酮类抗生素。

Objective： To evaluate the clinical value of pazufloxacin and lciprofloxacin in the treatment of hospital-acquired pneumonia Methods： A prospective parallel randomized controlled clinical study was conducted to compare the efficacy and safety with that of pazufloxacin and ciprofloxacin were administered intravenously at a dosage of 300mg and 200mg respectively twice daily for 7~10 days Results： The cure rates（77.59% vs 53.45%）,overall clinical efficacious rates（89.66% vs 74.14%）,total bacterial removal rates（93.02% vS 80.1%） pseudomonas aeruginosa removal rates（98.15% vs 75.0%）and Klebsiella pneumoniae removal rates（97.78% vs 85.7%）of the pazufloxacin group were superior to the ciprofloxacin group（P0.05 or P0.01） The incidence of adverse drug reactions of pazufloxacin group were less than ciprofloxacin group（15.52% vs 27.59%） with a statistics difference（P0.05）.No serious adverse event was reported in either group Conclusion： The pazufloxacin is effective and safe for the treatment of HAP,and it was superior to that of ciprofloxacin,especially to pseudomonas aeruginosa and Klebsiella pneumoniae removal The rates of adverse effect were small in pazufloxacin groups.Therefor,pazufloxacin was more relevant to popular pathogen of HAP than ciprofloxacin.